Atorvastatin cuts anthracycline heart failure

Published Date: 08 Mar 2023

Atorvastatin 40 mg daily for 12 months reduces cardiovascular events in lymphoma patients treated with anthracyclines.

Read Full News

Latest News

Cruise Ship Outbreak Raises Andes Virus Spread Concerns

European health agencies are monitoring passengers and crew members after suspected hantavirus exposure raised concerns about rare human transmission patterns.

Early Physical Activity Safe After MI

Patients who started physical activity within a week of discharge for a heart attack have no greater cardiovascular risk than less active patients in a recent study.

Long Delays in Cardiac Amyloidosis Diagnosis Persist

Most older adults with transthyretin cardiac amyloidosis face a several-month delay in diagnosis after a heart failure diagnosis, despite overall increased diagnostic frequency of amyloidosis.

Preventive Care With the Most Bang for Your Buck

An analysis of USPSTF and ACIP recommendations shows wide variation in impact, helping clinicians prioritize care during time-constrained visits.

Jehovah’s Witnesses Allow Autologous Blood in Brazil

Jehovah’s Witnesses now allow members to choose to use their own blood in some procedures, reigniting debate over bloodless surgery, patient autonomy, and broader blood-conservation care.

Clopidogrel Beats Aspirin Long-Term After PCI

When dual antiplatelet therapy was stopped 12 months after PCI, clopidogrel monotherapy lowered cardiovascular and bleeding events relative to aspirin.

Todays Updates

Only 1 in 4 Eligible Adults Receive Lung Screening

Complicated eligibility rules, stigma surrounding smoking and lung cancer, and confusion about the screening process continue to keep many high-risk patients from getting screened.

Low PSA May Not Fully Predict Survival in Prostate Cancer

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

FDA Warns of Secondary Blood Cancer Risk With Tazverik

The FDA says the increased risk of hematologic secondary primary malignancies with tazemetostat now outweighs the benefits of the drug; Ipsen pulls it from the market.

FDA Approves Next-Gen Agent for Mantle Cell Lymphoma

The BCL-2 inhibitor was granted accelerated approval based on findings from the phase 1/2 BGB-11417-201 study.

Todays Updates

Only 1 in 4 Eligible Adults Receive Lung Screening

Complicated eligibility rules, stigma surrounding smoking and lung cancer, and confusion about the screening process continue to keep many high-risk patients from getting screened.

Low PSA May Not Fully Predict Survival in Prostate Cancer

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

FDA Warns of Secondary Blood Cancer Risk With Tazverik

The FDA says the increased risk of hematologic secondary primary malignancies with tazemetostat now outweighs the benefits of the drug; Ipsen pulls it from the market.

FDA Approves Next-Gen Agent for Mantle Cell Lymphoma

The BCL-2 inhibitor was granted accelerated approval based on findings from the phase 1/2 BGB-11417-201 study.

Latest News

European health agencies are monitoring passengers and crew members after suspected hantavirus exposure raised concerns about rare human transmission patterns.

Patients who started physical activity within a week of discharge for a heart attack have no greater cardiovascular risk than less active patients in a recent study.

Most older adults with transthyretin cardiac amyloidosis face a several-month delay in diagnosis after a heart failure diagnosis, despite overall increased diagnostic frequency of amyloidosis.

An analysis of USPSTF and ACIP recommendations shows wide variation in impact, helping clinicians prioritize care during time-constrained visits.

Jehovah’s Witnesses now allow members to choose to use their own blood in some procedures, reigniting debate over bloodless surgery, patient autonomy, and broader blood-conservation care.

When dual antiplatelet therapy was stopped 12 months after PCI, clopidogrel monotherapy lowered cardiovascular and bleeding events relative to aspirin.

News All Time

Assess, Align, Act: A Practical Guide to ASCVD Risk Assessment and LDL-C Goal Setting

Assess, Align, Act: A Practical Guide to ASCVD Risk Assessment and LDL-C Goal Setting

ACC: American College of Cardiology

HRS: Heart Rhythm Society

Exercise According to Chronotrope Type; Estimating Kidney Function

Also in TTHealthWatch: deprescribing proton pump inhibitors

What a New Study Shows About Brain Health and GLP-1 Drugs

By extending survival, GLP-1 agents may expand the dementia risk period for diabetes patients

Midlife Migraines Tied to Higher Dementia Risk, 40-Year Study Suggests

Findings add to the evidence exploring whether migraines and dementia are connected

One Troponin Assay Would Suggest Whopping MI Incidence After Cardiac Surgery

Choice of cTnI versus cTnT is a source of contention, as is the cTn threshold for defining MI

Napping and Mortality Risk; Senator's Daughter Dies; Video Game Triage in the ED

Health news and commentary gathered by MedPage Today staff

Best Exercise Timing; GLP-1 Pill's Heart Safety; Pop Star's Cardiovascular Illness

Recent developments of interest in cardiovascular medicine

Triple Pill Gets Intracerebral Hemorrhage Survivors Closer to BP Goals

TRIDENT trial tested a polypill containing three antihypertensive drugs at low doses

Diabetic 'Dumped' at Shelter; The Opioid Victims Getting $0; Clade I Mpox on Flights

Health news and commentary gathered by MedPage Today staff

Think Heart Attacks Cause Most Sudden Cardiac Deaths? Think Again, Study Says

Autopsy study shifts attention to other causes, highlights deficiencies in risk screening

FDA Expands Approval of Drug to Stave Off Type 1 Diabetes

Teplizumab now indicated for kids as young as 1 year with preclinical disease

Grieving and Heart Attacks; Fatal Hospital Shooting; Trump Admin Wants Firing Squads

Health news and commentary gathered by MedPage Today staff

Controlling Hypertension After Intracerebral Hemorrhage; Treating Acute Sinusitis

Also in TTHealthWatch: still a role for Paxlovid?

Study Sheds Light on Why Taking Vit D May Lower Diabetes Risk for Some

People with prediabetes and certain genetic profiles may benefit from high-dose supplementation

Recommended News For You

Unlocking the potential of targeted therapies for multiple myeloma

Combination of significant weight gain and late motherhood greatly increases risk of breast cancer, study finds

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

Shorter, less intense regimen still effective for HPV-linked throat cancer, study shows

Prior authorizations draining time, energy from many cancer patients

PSA Screening Overdiagnosis Rises Sharply With Age

Study sheds light on challenges for women of color after breast cancer surgery

Recommended Articles For You

Cardio-Oncology: Managing Heart Failure in Survivors of Cancer 

The Benefits and Risks of Thrombolytics: A Comprehensive Guide  

How Bispecific Antibodies are Redefining Medical Oncology in the US - A 2025 Review 

Expanding Oncology Frontiers: Rare Cancers, Breakthroughs, and Precision Medicine Advances 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

On all CAR-T products, the FDA is calling for a new boxed warning.

2.

A study has developed molecular markers that predict meningioma recurrence.

3.

Brexpiprazole Safe, Effective in Early-Episode Schizophrenia

4.

AI can identify women at risk of breast cancer years in advance: Study

5.

Advances in TNBC; Mixed News in Lung Cancer Report; Pancreatic Cancer Overdiagnosis?

1.

A Visual Journey Through Penile Cancer: Examining the Impact of Photos

2.

Unleashing the Inner Predator: Reprogramming Macrophages to Conquer Cancer Immunotherapy

3.

Unlocking the Immune Arsenal: A Revolution in Cancer Treatment

4.

The Growing Crisis of Aplastic Anemia: A Call for Action

5.

Interpreting Iron Studies: What Your Blood Results Really Mean 

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

First Line Combination Therapy- The Overall Survival Data in NSCLC Patients

2.

The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift

3.

INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients

4.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

5.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot